Keyword: Forbion Capital Partners
The financing tees up Enterprise to take three projects into the clinic and push one of them through a midphase proof-of-concept trial.
The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.
European VC firm Forbion, New Science Ventures and BioGeneration Ventures have helped bump up a $19 million series B round for Escalier Biosciences.
The haul makes BioDiscovery 5 the largest fund dedicated to biotechs and medical devices in Europe and tees up De Rothschild to invest in 17 firms.
The round reunites some of the executives and investors who helped Dezima and Akarna to takeovers by Amgen and Allergan, respectively.
The big biotech participated in the round to equip Hookipa to advance its cytomegalovirus vaccine and cancer candidate through early clinical testing.
The series B round equips the team that led BioVex to a $1 billion buyout by Amgen to take another crack at developing a cancer-fighting virus.
The series C tees Milestone up to test its intranasal calcium channel blocker etripamil in patients with paroxysmal supraventricular tachycardia.
Argenx’s IPO fundraising total has come to a stop at $144.7 million, more than 50% above its initial target.
Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.